A Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, 5-Period Crossover, Phase 1b Study To Evaluate The Effects Of Single Oral Administration of TAK-071 On Scopolamine-Induced Cognitive Impairment In Healthy Subjects

Trial Profile

A Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, 5-Period Crossover, Phase 1b Study To Evaluate The Effects Of Single Oral Administration of TAK-071 On Scopolamine-Induced Cognitive Impairment In Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs TAK 071 (Primary) ; Donepezil; Scopolamine
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 18 Apr 2017 Trial design changed ffrom 4 period crossover to 5 period crossover. Treatment arms has been changed from 4 to 11
    • 18 Apr 2017 Planned number of patients changed from 32 to 46.
    • 18 Apr 2017 Planned End Date changed from 1 Sep 2017 to 13 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top